At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia
In Brief
A Phase 4 clinical trial evaluating Telmisartan, Placebo, and 2 other interventions for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 66 participants across 1 site.
Detailed Summary
This is a 12-week, randomized, double-blinded, placebo-controlled trial of telmisartan 80 mg/day as an adjunctive to clozapine or olanzapine therapy, in 70 schizophrenia subjects to examine telmisartan's effect on glucose metabolism, weight, food intake, resting energy expenditure, and body composition. In addition, the study will examine insulin's effects on psychopathology and cognition. Potential subjects will be identified by their clinicians at the Freedom Trail Clinic, or Massachusetts General Hospital. Approximately 70 subjects will be enrolled.
Study Details
Timeline
Interventions
Telmisartan 40mg/day for the first 2 weeks. Telmisartan 80mg/day for the next 10 weeks.
Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
Clozapine (plus telmisartan or placebo) for 12 weeks.
Olanzapine (plus telmisartan or placebo) for 12 weeks.